Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction.
Título
Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction.
Autor
Wenyu Fu, Yujianan Chen, Kaidi Wang, Aubryanna Hettinghouse, Wenhuo Hu, Jing-Quan Wang, Zi-Ning Lei, Zhe-Sheng Chen, Kenneth A Stapleford, Chuan-Ju Liu
Fecha
2020
Identificador
10.1007/s13238-020-00803-w
Fuente
Protein & Cell
Editor
SpringerOpen
Archivos
Colección
Citación
Wenyu Fu, Yujianan Chen, Kaidi Wang, Aubryanna Hettinghouse, Wenhuo Hu, Jing-Quan Wang, Zi-Ning Lei, Zhe-Sheng Chen, Kenneth A Stapleford, Chuan-Ju Liu, “Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction.,” SOCICT Open, consulta 17 de abril de 2026, https://www.socictopen.socict.org/items/show/8116.
Position: 13021 (22 views)